Trial Profile
A Prospective, Multicentre, Open-label, Randomised Phase 2 Trial to Study the Efficacy and Safety of Anlotinib Hydrochloride Versus Imatinib Mesylate in Locally Advanced, Unresectable or Metastatic Chordoma
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 09 Aug 2022
Price :
$35
*
At a glance
- Drugs Catequentinib (Primary) ; Imatinib
- Indications Chordoma
- Focus Therapeutic Use
- 06 Aug 2019 New trial record